AR and prostate carcinoma: Potent androgen receptor (AR) pathway inhibitors (ARPIs), such as enzalutamide (ENZ) and abiraterone (Abi), have increased patient survival with advanced prostate cancer disease;1,2 however, resistance ultimately occurs.